

Autism Spectrum Disorder

The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan

Trial Status
Withdrawn

Trial Runs In
0 Countries

Trial Identifier
NCT03912350 WP41045

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is a multi-center, non-randomized, open-label, parallel group, multiple-dose study to assess the pharmacokinetic, safety, and tolerability of balovaptan in male and female subjects with moderate hepatic impairment compared to healthy subjects with normal hepatic function matched by age (± 10 years), sex, and body mass index (BMI; $\pm 20\%$).

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT03912350 WP41045
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
 ≥ 18 Years & ≤ 75 Years

Healthy Volunteers
Accepts Healthy Volunteers
